share_log

BioNTech | 6-K: BioNTech and DualityBio Receive FDA Fast Track Designation for Antibody-Drug Conjugate Candidate BNT324/DB-1311 in Prostate Cancer

BioNTech | 6-K: BioNTech and DualityBio Receive FDA Fast Track Designation for Antibody-Drug Conjugate Candidate BNT324/DB-1311 in Prostate Cancer

BioNTech | 6-K:BioNTech 和DualityBio獲得FDA對前列腺癌抗體藥物偶聯候選物BNT324/DB-1311的快速通道認證
美股sec公告 ·  06/24 08:10
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息